[PDF][PDF] A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain …
K Schreck, S Grossman, BM Ellingson, X Ye - cdn.clinicaltrials.gov
Primary Objective Estimate the efficacy of combination treatment with encorafenib and
binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF …
binimetinib, as measured by response rate (RANO criteria), in patients with recurrent BRAF …
Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma
Purpose: Although fewer than 5% of high-grade gliomas (HGG) are BRAF-V600E mutated,
these tumors are notable as BRAF-targeted therapy shows efficacy for some populations …
these tumors are notable as BRAF-targeted therapy shows efficacy for some populations …
Ctni-60. preliminary results of binimetinib and encorafenib in adults with recurrent Braf V600e-mutated high-grade glioma
BACKGROUND Although< 5% of high-grade gliomas (HGG) are BRAF-V600E mutated,
these tumors are being identified more frequently as genetic testing increases in gliomas …
these tumors are being identified more frequently as genetic testing increases in gliomas …
Complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a …
Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-
mutant glioma, with high overall response and manageable toxicity. We described a …
mutant glioma, with high overall response and manageable toxicity. We described a …
CTNI-61. Clinical efficacy and predictive biomarkers of ONC201 in H3K27M-mutant diffuse midline glioma
AR Kawakibi, R Tarapore, S Gardner, A Chi… - Neuro …, 2022 - academic.oup.com
Abstract BACKGROUND Although< 5% of high-grade gliomas (HGG) are BRAF-V600E
mutated, these tumors are being identified more frequently as genetic testing increases in …
mutated, these tumors are being identified more frequently as genetic testing increases in …
INNV-03. EFFICACY AND LONG-TERM OUTCOMES IN THE MANAGEMENT OF LARGE BRAIN METASTASIS (≥ 4 CM3) USING 2-STAGED STEREOTACTIC …
Y Hori, S Yomo, W Wei, J Avecillas-Chasin… - Neuro …, 2020 - academic.oup.com
BACKGROUND Up to 65% of anaplastic pleomorphic xanthoastrocytomas (A-PXA) harbor
the BRAFV600E oncogene. Trials and case series have demonstrated that BRAF-mutant …
the BRAFV600E oncogene. Trials and case series have demonstrated that BRAF-mutant …
No drug holidays in BRAFV600E glioma patients: an argument for dose reduction of targeted therapies
DA Bazer, A Kolchinski, NAO Bush… - Neuro-Oncology …, 2024 - academic.oup.com
Abstract Background Combined BRAF and MEK inhibition is effective for some BRAFV600E
altered gliomas, a cancer for which there are few effective therapies. While recent clinical …
altered gliomas, a cancer for which there are few effective therapies. While recent clinical …
INNV-06. BRAF AND MEK DUAL INHIBITORS THERAPY IN RECURRENT OR ANAPLASTIC PLEOMORPHIC XANTHOASTROCYTOMA (PXA)
K Kata, JCR Quintero, O Arevalo-Espejo… - Neuro …, 2021 - ncbi.nlm.nih.gov
METHODS Medical records from 2010 to 2021 in Memorial Hermann Texas Medical Center
were reviewed. Patients diagnosed with PXA who received BRAF and/or MEK inhibitors …
were reviewed. Patients diagnosed with PXA who received BRAF and/or MEK inhibitors …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
PY Wen, A Stein, M van den Bent, J De Greve… - The lancet …, 2022 - thelancet.com
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
Background High-grade gliomas (HGG) with BRAF V600E mutation represent a unique
subset of central nervous system tumors. Targeted therapies including BRAF and MEK …
subset of central nervous system tumors. Targeted therapies including BRAF and MEK …